SRS Capital Advisors Inc. lessened its holdings in Becton Dickinson and Co (NYSE:BDX) by 15.7% during the third quarter, Holdings Channel reports. The fund owned 1,503 shares of the medical instruments supplier’s stock after selling 279 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Becton Dickinson and were worth $392,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Dupont Capital Management Corp boosted its holdings in Becton Dickinson and by 9.2% in the 3rd quarter. Dupont Capital Management Corp now owns 83,126 shares of the medical instruments supplier’s stock worth $21,696,000 after buying an additional 6,977 shares during the period. S&CO Inc. bought a new position in Becton Dickinson and in the 3rd quarter worth approximately $215,000. Penserra Capital Management LLC boosted its holdings in Becton Dickinson and by 16.5% in the 3rd quarter. Penserra Capital Management LLC now owns 1,840 shares of the medical instruments supplier’s stock worth $480,000 after buying an additional 260 shares during the period. IFG Advisory LLC boosted its holdings in Becton Dickinson and by 13.7% in the 3rd quarter. IFG Advisory LLC now owns 2,248 shares of the medical instruments supplier’s stock worth $586,000 after buying an additional 271 shares during the period. Finally, Suncoast Equity Management bought a new position in Becton Dickinson and in the 3rd quarter worth approximately $224,000. Institutional investors own 92.60% of the company’s stock.

Shares of NYSE:BDX opened at $243.26 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87. The firm has a market capitalization of $63.38 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.46 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the firm earned $2.40 EPS. The business’s quarterly revenue was up 39.0% compared to the same quarter last year. On average, equities analysts expect that Becton Dickinson and Co will post 12.2 earnings per share for the current fiscal year.

In other Becton Dickinson and news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP James C. Lim sold 5,189 shares of the firm’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.

Several research analysts recently commented on the stock. Barclays set a $260.00 price objective on shares of Becton Dickinson and and gave the stock a “hold” rating in a report on Thursday. Citigroup raised their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Piper Jaffray Companies cut their price objective on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a report on Tuesday. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Morgan Stanley raised their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus target price of $254.07.

WARNING: “SRS Capital Advisors Inc. Has $392,000 Position in Becton Dickinson and Co (BDX)” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dailypolitical.com/2018/11/10/srs-capital-advisors-inc-has-392000-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Find a Trading Strategy That Works

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.